Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis

BACKGROUND: For patients with inadequate control of cholesterol using moderate-dose statins in the secondary prevention of cardiovascular diseases (CVD), either doubling the dose of statins or adding ezetimibe should be considered. The cost-effectiveness of them is unknown in the Chinese context. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Han, Li, Nan, Zhou, Youlian, Xiao, Zhilan, Tian, Haoming, Hu, Ming, Li, Sheyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969683/
https://www.ncbi.nlm.nih.gov/pubmed/32021100
http://dx.doi.org/10.2147/DDDT.S213968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969683/
https://www.ncbi.nlm.nih.gov/pubmed/32021100
http://dx.doi.org/10.2147/DDDT.S213968

Ejemplares similares